Axcella

Axcella Health is a clinical-stage biotechnology company pioneering a novel approach to treat complex diseases and improve health using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates consist of EMMs and their derivatives, which are designed in different combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for nonalcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy (OHE) recurrence.